Beginning with the January 2024 issue, Neurotherapeutics will become a fully Open Access journal in keeping with the overall trend in scientific publishing. Over the years, the official journal of the American Society for Experimental Neurotherapeutics (ASENT) has gone through a number of transitions regarding its publishing model, beginning with traditional subscription-based print journal paid by libraries, universities, and other institutions, then hybrid online publishing with both subscription and open access options, and now moving to fully open access where the cost of publishing will be covered by authors, their funders, or institutions. Invited articles will not be subject to Article Processing Charges. Along with this change, Elsevier will now be the new publisher of Neurotherapeutics. Manuscripts can be submitted for consideration at https://www.editorialmanager.com/neurot/default2.aspx.

The benefits of Open Access publishing are clear. By making all our content freely available to the scientific community and the public, we are expanding our reach globally and expediting the delivery of this knowledge immediately upon online publication. This will equalize access to this information to all and help accelerate the discovery and development of new and improved treatments for neurological disorders. This new publishing model will also support contributing authors. Many funding agencies now require researchers to make their findings fully accessible to the public without delay. Once proofs are approved by authors, all accepted articles will be posted on the Journal website at https://www.sciencedirect.com/journal/neurotherapeutics.

The Journal’s editorial policy, standards, and processes remain the same. Special issues comprise a set of invited thematic critical reviews of broad interest on current and emerging treatments for neurologic disorders. The Journal also publishes current perspectives and commentaries on hot topics by invited key opinion leaders as well as unsolicited original research articles on preclinical, translational, and clinical investigations of wide-ranging neurological disorders. Peer review will continue to be rigorous, efficient, and constructive. The Journal continues to grow in volume, readership, and downloads.

The Journal leadership remains the same. I am delighted to have a distinguished team of Associate Editors including Gregory K. Bergey, MD, Director of the Johns Hopkins Epilepsy Center; Steven T. DeKosky, MD, Deputy Director of the McKnight Brain Institute and Aerts-Cosper Professor of Alzheimer’s Research at the University of Florida College of Medicine; and W. Taylor Kimberly, MD, PhD, Chief, Division of Neurocritical Care at Massachusetts General Hospital and Harvard Medical School. Editorial Manager Linda Powell will continue to run the editorial office as she has done with great dedication since the launch of the Journal.

I would also like to express my gratitude to our editorial board members and external peer reviewers who are instrumental in maintaining the highest standards of publications.

I look forward to this new partnership with Elsevier and anticipate that we will continue to grow, while upholding our rigorous scientific standards and accessibility to clinicians and researchers worldwide.